What one share of Larimar Therapeutics holds
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (“CPP”) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (“FXN”), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”).
Larimar Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.24 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.12 |
| Cash and investments | $0.89 |
| Book value | $1.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.00 | −$3.80 | $0.01 | −$3.74 | — | −$0.11 |
| 2020 | — | −$3.58 | $0.01 | −$3.56 | — | $5.84 |
| 2021 | — | −$2.95 | $0.02 | −$2.47 | — | $3.64 |
| 2022 | — | −$1.37 | $0.00 | −$1.07 | — | $2.56 |
| 2023 | — | −$0.84 | $0.00 | −$0.77 | — | $1.86 |
| 2024 | — | −$1.32 | $0.01 | −$1.16 | — | $2.69 |
| 2025 | — | −$1.19 | $0.00 | −$0.81 | — | $0.94 |
Common questions about Larimar Therapeutics
How much does one share of Larimar Therapeutics earn?
Over the last 12 months, Larimar Therapeutics lost $1.24 for each share.
Does Larimar Therapeutics pay a dividend?
Larimar Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Larimar Therapeutics’s book value per share?
Larimar Therapeutics’s book value is $1.23 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Larimar Therapeutics have?
Each share of Larimar Therapeutics has $0.89 of cash and investments, as of June 30, 2026.
What is Larimar Therapeutics’s free cash flow per share?
−$1.12 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Larimar Therapeutics bought back shares?
Larimar Therapeutics’s share count rose about 2186% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.